Interleukin-2 injections produce sustained increases in CD4+ T cell counts in early-stage HIV

October 1996
AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p312
Academic Journal
States advantages of self-administered injections of interleukin-2 in increasing the mean CD4 T counts in the research in early HIV infection at National Institute of Allergy and Infectious Diseases. Studies in combination with antiretroviral drugs; Toxicities from mild to moderate flu-like symptoms; Positive results anticipating phase III trial in determining drug efficacy.


Related Articles

  • Encouraging data on quality of life reported for IL-2 therapy.  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p314 

    Reports findings of a study on the quality of life of HIV-infected patients receiving intravenous interleukin-2 (IL-2) as opposed to oral intake of IL-2. Absence of overall difference in quality of life or symptom distress in both groups; Mild to moderate flu-like symptoms.

  • Interleukin-2 therapy in HIV infection. Pahwa, Savita; Morales, Maripaz // AIDS Patient Care & STDs;Mar1998, Vol. 12 Issue 3, p187 

    Examines the use of interleukin-2 (IL-2) therapy in patients infected with human immunodeficiency virus (HIV). Identification of the role of cytokines in the immune system; Use of interleukin in cancer therapy; Description of mechanisms of IL-2.

  • VIRAL REBOUND DESPITE HAART AND IL-2.  // AIDS Patient Care & STDs;Feb2000, Vol. 14 Issue 2, p101 

    Presents research findings showing that two patients treated with highly active antiretoviral therapy (HAART) regimens and interleukin-2 (IL-2) and who had undetectable viral loads, had quick viral rebound soon after stopping therapy. Support of earlier reports that eradicating HIV from the...

  • Benefit of IL-2 Therapy in HIV Patients Confirmed. Abrams, Donald; Chatfield, Joanne E. // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2424 

    Reports on the confirmation that recombinant interleukin-2 produces a sustained increase in the CD4+ T-cell level for up to one year in some patients with human immunodeficiency virus infection who are receiving antiretroviral drug therapy. Demonstration that the addition of recombinant...

  • IL-2 in HIV Infection: Raises CD4+ Cells, But at What Cost? Winslow, Dean L. // AIDS Alert;Jul2007, Vol. 22 Issue 7, p82 

    Actg 328 was a multicenter trial that studied HIV-1 infected adults without active AIDS-defining illnesses and with CD4+ lymphocyte counts between 50 and 350/uL. Patients were protease inhibitor (PI) and IL-2 naive but may have received prior nucleoside analogue therapy. Patients were treated...

  • Up with T cells.  // Advocate;4/4/95, Issue 678, p12 

    Cites research findings on the use of off-and-on infusions of the natural protein interleukin 2 (IL-2) to boost the immune systems of people with HIV. Side effects of the treatment.

  • Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Chun, Tae-Wook; Engel, Delphine; Mizell, Stephanie B.; Hallahan, Claire W.; Fischette, Maria; Park, Sohee; Davey, Richard T.; Dybul, Mark; Kovacs, Joseph A.; Metcalf, Julia A.; Mican, JoAnn M.; Berrey, M. Michelle; Corey, Lawrence; Lane, H. Clifford; Fauci, Anthony S. // Nature Medicine;Jun1999, Vol. 5 Issue 6, p651 

    The size of the pool of resting CD4[sup +] T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus highly active anti-retroviral therapy (HAAET) was significantly lower than that of patients receiving HAAET alone. Virus could not be...

  • Latent reservoirs of HIV infection: Flushing with IL-2? Cooper, David A.; Emery, Sean // Nature Medicine;Jun1999, Vol. 5 Issue 6, p611 

    A new study suggests it may be possible to further dilute quantities of infectious HIV in infected people by combining potent anti-retroviral therapy with immune therapy using interleukin-2 (pages 651?655).

  • Reversing HIV damage `possible'. Aldhous, Peter // New Scientist;3/11/95, Vol. 145 Issue 1968, p9 

    Reports on the possibility of reversing the damage of HIV to the immune system by using interleukin-2. Results of the research conducted by scientists at the National Institutes of Health in Bethesda, Maryland concerning the reversal of the decline in CD4 cells caused by HIV.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics